CDKN2A and cancer: Because the true CDKN2A CDR was observed in more than 90% of CDKN2A-deleted cancer samples and the P16-Light assay is highly reproducible and convenient, the quantitative P16-Light assay should be considered a viable assay for detecting CDKN2A SCNVs in clinical practice.